US2010158867A1PendingUtilityA1

Paramyxovirus vector encoding angiogenesis gene and use thereof

Assignee: DNAVEC RESEARCH INCPriority: Nov 27, 2000Filed: Sep 30, 2009Published: Jun 24, 2010

Est. expiryNov 27, 2020(expired)· nominal 20-yr term from priority

Inventors:Yoshikazu Yonemitsu Katsuo Sueishi Masayuki Fukumura Xiaogang Hou Mamoru Hasegawa Hidenori Matsusaka Hiroyuki Tsutsui

A61P 9/10A61P 9/00C12N 2760/18843C12N 2800/30C12N 15/86C07K 14/50A61K 48/00

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.

Claims

exact text as granted — not AI-modified

1 . A Paramyxovirus vector encoding an angiogenic gene capable of being expressed.

2 . The Paramyxovirus vector of claim 1 , wherein the angiogenic gene is fibroblast growth factor 2 (FGF2).

3 . The Paramyxovirus vector of claim 1 , wherein the Paramyxovirus is Sendai virus.

4 . The Paramyxovirus vector of claim 1 , wherein said vector lacks the F gene.

5 . An angiogenic composition comprising the Paramyxovirus vector of claim 1 or a cell containing the vector, and a pharmaceutically acceptable carrier.

6 . An angiogenic composition comprising the Paramyxovirus vector of claim 2 or a cell containing the vector, and a pharmaceutically acceptable carrier.

7 . An angiogenic composition comprising the Paramyxovirus vector of claim 3 or a cell containing the vector, and a pharmaceutically acceptable carrier.

8 . An angiogenic composition comprising the Paramyxovirus vector of claim 4 or a cell containing the vector, and a pharmaceutically acceptable carrier.

9 . A method for inducing angiogenesis, wherein said method comprises the step of administering the angiogenic composition of claim 5 to a subject in need of angiogenesis.

10 . A method for inducing angiogenesis, wherein said method comprises the step of administering the angiogenic composition of claim 6 to a subject in need of angiogenesis.

11 . A method for inducing angiogenesis, wherein said method comprises the step of administering the angiogenic composition of claim 7 to a subject in need of angiogenesis.

12 . A method for inducing angiogenesis, wherein said method comprises the step of administering the angiogenic composition of claim 8 to a subject in need of angiogenesis.

13 . The method of claim 9 , wherein the angiogenic composition is intramuscularly injected.

14 . A method of treating ischemic tissues, wherein said method comprises the step of administering the angiogenic composition of claim 5 to a subject in need of angiogenesis, thereby inducing angiogenesis.

15 . A method of treating ischemic tissues, wherein said method comprises the step of administering the angiogenic composition of claim 6 to a subject in need of angiogenesis.

16 . A method of treating ischemic tissues, wherein said method comprises the step of administering the angiogenic composition of claim 7 to a subject in need of angiogenesis.

17 . A method of treating ischemic tissues, wherein said method comprises the step of administering the angiogenic composition of claim 8 to a subject in need of angiogenesis.

18 . The method of claim 14 , wherein the angiogenic composition is intramuscularly injected.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.